Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.94 |
| ▸ | HTR1A | P08908 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | JAK2 | O60674 | 1/20 | 0.68 |
| ▸ | MPO | P05164 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | HTR2B | P41595 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | HTR1D | P28221 | 3/20 | 0.62 |
| ▸ | HTR1B | P28222 | 3/20 | 0.62 |
| ▸ | BCHE | P06276 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | DRD4 | P21917 | 1/20 | 0.61 |
| ▸ | DRD5 | P21918 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29543272 | 1.00 | HTR2A (0.94) | HTR2AHTR1ALMNAHTTKDM4E | |
| SCHEMBL32669458 | 0.98 | HTR2A (0.91) | HTR2AHTR1ALMNAHTTKDM4E | |
| SCHEMBL734226 | 0.98 | HTR2A (0.91) | HTR2AHTR1ALMNAHTTKDM4E | |
| SCHEMBL25295661 | 0.97 | HTR2A (1.00) | HTR2AHTR1ALMNAHTTKDM4E | |
| SCHEMBL6465788 | 0.93 | HTR2A (0.88) | HTR2AHTR1ALMNAHTTRAB9A | |
| SCHEMBL2259204 | 0.91 | HTR1A (0.88) | HTR2AHTR1ALMNAHTTKDM4E | |
| SCHEMBL5170230 | 0.89 | HTR1A (0.81) | HTR2AHTR1ALMNAHTTKDM4E | |
| SCHEMBL2420293 | 0.89 | HTR1A (0.86) | HTR2AHTR1ALMNAHTTKDM4E | |
| SCHEMBL20244861 | 0.88 | HTR2A (0.78) | HTR2AHTR1AMPOBCHECYP2D6 | |
| SCHEMBL735143 | 0.88 | HTR2A (0.78) | HTR2AHTR1AMPOHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | KULEON LLC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | Park City Bio, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-12564560-B1 | Selective serotonin receptor modulators and methods of making and using the same | Park City Bio, LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250376436-A1 | Selective Serotonin Receptor Modulators and Methods of Making and Using the Same | Park City Bio, LLC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250340513-A1 | NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS | KULEON LLC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12441683-B2 | 7-methyl indole analogs and dosage forms containing the same | Kuleon, LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250289817-A1 | SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2025-09-18 | — | — | US | disclosed |
| US-12414936-B2 | Compositions comprising a serotonergic tryptamine compound | CAAMTECH, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250282722-A1 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | KULEON LLC (US) | 2025-09-11 | — | — | US | disclosed |
| WO-2022115798-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20210361679-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2021-11-25 | — | — | US | disclosed |
| US-20210346346-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2021-11-11 | — | — | US | disclosed |
| US-20190142851-A1 | COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID | CAAMTECH, INC. | 2019-05-16 | — | — | US | disclosed |
| CN-101516844-B | 4-heteroaryl substituted 1-aminocyclohexane-1-and cyclohexene-1-derivatives having activity on opioid receptor systems | GRUENENTHAL GMBH | 2013-12-11 | — | — | CN | disclosed |
| EP-2044016-B1 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | GRUENENTHAL GMBH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-8138187-B2 | Substituted heteroaryl derivatives | GRUENENTHAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | GRUNENTHAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| EP-1638934-B1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | LILLY CO ELI (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007071840-A2 | COMPOUNDS BASED ON FOUR AROMATIC RINGS, PREPARATION AND USES THEREOF | CEREP (FR) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142851-A1 | COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID | CNR1, CNR2, HTR5A | HTR2A 6/4885HTR1A 5/4885LMNA 4051/4885 |
| US-20250376436-A1 | Selective Serotonin Receptor Modulators and Methods of Making and Using the Same | HTR1A, HTR4, HTR5A | HTR2A 8/4885HTR1A 1/4885LMNA 4470/4885 |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | HTR2C, HTR7, HTR6 | HTR2A 6/4885HTR1A 5/4885LMNA 1679/4885 |
| US-20250282722-A1 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | HTR7, HTR2C, HTR1A | HTR2A 8/4885HTR1A 3/4885LMNA 3634/4885 |
| US-20250289817-A1 | SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | HTR5A, HTR1A, HTR3A | HTR2A 5/4885HTR1A 2/4885LMNA 4174/4885 |
| US-20210346346-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | HTR3A, HTR2A, HTR5A | HTR2A 2/4885HTR1A 5/4885LMNA 1161/4885 |
| US-12441683-B2 | 7-methyl indole analogs and dosage forms containing the same | HTR7, HTR2C, HTR1A | HTR2A 8/4885HTR1A 3/4885LMNA 3634/4885 |
| US-12414936-B2 | Compositions comprising a serotonergic tryptamine compound | HTR3A, HTR2A, HTR5A | HTR2A 2/4885HTR1A 5/4885LMNA 1161/4885 |
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | CYP3A43, HMGCR, ABCG2 | HTR2A 238/4885HTR1A 746/4885LMNA 1488/4885 |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | ADRA2C, ADRB3, ADRA2B | HTR2A 19/4885HTR1A 22/4885LMNA 1573/4885 |
| US-20250340513-A1 | NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS | HTR2A, HTR2C, HTR3A | HTR2A 1/4885HTR1A 4/4885LMNA 3694/4885 |
| US-20210361679-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | HTR3A, HTR2A, HTR5A | HTR2A 2/4885HTR1A 5/4885LMNA 1161/4885 |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | HTR1D, HTR1A, HTR4 | HTR2A 14/4885HTR1A 2/4885LMNA 3563/4885 |
| US-12564560-B1 | Selective serotonin receptor modulators and methods of making and using the same | HTR5A, HTR1A, HTR1D | HTR2A 16/4885HTR1A 2/4885LMNA 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.